"With regard to the situation of the administration of the vaccine against Covid-19, it should be noted that Italy has already vaccinated almost 180 thousand people. Only yesterday, with all the Regions that have launched the campaign, over 65 thousand doses were administered , a record figure within the European Union. The Italian numbers are already satisfactory today, because they place our country in second place in the continent for the quantity of doses administered ".
Sources from Palazzo Chigi underline this.
On the administration of vaccines "the organizational machine is accelerating and, within a few weeks, will travel at full speed", explain sources from Palazzo Chigi, recalling that Italy is already second in the EU "behind only Germany, which however has could count on a higher initial endowment ".
"A result for which we must thank the exceptional work of the women and men of our National Health System. We continue to engage in this great effort to create an unprecedented vaccination plan!", They explain again.
"We are in two important programs:
Pfizer and AstraZeneca
. And Ema's authorization for what we know is imminent: we do not hang in the days but it arrives". Minister Luigi Di Maio said to "Today is another day" on Rai 1.
"We are in two important programs and now the testing phase of the Italian vaccine has also ended".
Italy is able in an absolutely competitive way to play important games on the ability to generate sophisticated biomedical technology,
said the president of the Css
Franco Locatelli
at the presentation to the Spallanzani Institute of the
results of Phase 1 of the experimentation of the Italian anti-Covid vaccine ReiThera GRAd-CoV2
.
"
We aim to develop 100 million doses of the vaccine per year
. The vaccine is stable at a temperature between 2 and 8 degrees," said the president of the Italian vaccine developer Reithera, Antonella Folgore.
"We enrolled 100 people and 45 were vaccinated with different doses and all made it to the end for the safety assessment: the vaccine had no serious adverse events in the first 28 days after vaccination, a better result than Moderna and Pfizer who have had side effects. The peak of antibody production at 4 weeks remains constant and the vaccine is a single dose ".
This was stated by
the scientific director of Spallanzani Giuseppe Ippolito
at the presentation of the results of Phase 1 of the experimentation of the Vaccine GRAd-CoV2 of ReiThera.
In this phase 1 the Reithera vaccine "has been shown to be safe, to have the ability to induce immune response in adults and the response is similar to that of other two-dose vaccines. 92.5% of vaccinated had detectable antibody levels and with a single dose we have results in line with Moderna and Pfizer, "added Ippolito to the presentation of the phase 1 data of the Italian vaccine ReiThera.
The levels of antibodies, said Ippolito, "are consistent with a single administration scheme and are likely to increase with other doses. Now we expect phase 2 for which the commitment of the state is required".
"92.5% of the vaccinees developed detectable antibodies. Comparing the data from this study with Moderna and Pfizer we are in line and expect the vaccine's ability to prevent disease substantially like other vaccines. We will submit the protocol to regulatory agencies. in a short time and hypothesis is to close phase 3 by the summer ",
explained the scientific director of Spallanzani Ippolito
.
"Comparing the data of the Italian vaccine ReiThera with the data of the anti-Covid vaccines of Moderna and Pfizer - explained Giuseppe
Ippolito
-, we see that with a single dose we have absolutely in line results. But what will be the final dosage will decide in the end of all phases of experimentation ".
"Let's try to achieve some independence also in the vaccine supply",
underlined
Domenico Arcuri, extraordinary commissioner for the Covid-19 emergency
in the press conference.
"The Government has allocated sufficient resources to finance the subsequent development of the ReiThera experiment - he explained -. The Government, through a public company, will also enter ReiThera with an equity operation, and the development contracts will be used to finance research and a incremental stabilization of production ".
"The first results of the vaccine developed by ReiThera and tested at the Spallanzani Institute are encouraging
. If the data obtained so far are confirmed, we will have in the coming months an effective and safe vaccine with a single dose instead of two doses. It will be produced entirely in our country. . It is important to continue investing in Italian research and its scientific excellence ". These are the words of the Minister of Health,
Roberto Speranza
, at the presentation of the results of the ReiThera vaccine at the Spallanzani hospital.